secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cabaletta Bio, Inc. (CABA)
CIK:        0001759138
Form:       8-K
Filed at:   2026-03-23T23:59:59+00:00
Accession:  0001759138-26-000010
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cabaletta Bio Q4/FY2025 cash $133.6M; myositis BLA on track for 2027; $30M raise
--------------------------------------------------------------------------------

- Q4 R&D expenses $36.2M, FY R&D $142.7M; cash $133.6M as of Dec 31, 2025; raised additional $30M in Q1 2026.
- Registrational DM/ASyS cohort enrolling (17 patients); BLA submission for rese-cel in myositis targeted for 2027.
- No-preconditioning rese-cel data from RESET-SLE expected 1H26 (initial) and 2H26 (durability); PV durability data throughout 2026.
- Automated manufacturing with Cellares: initial clinical data expected 1H26; potential to produce for thousands per year.
- Complete Phase 1/2 data from RESET-SSc, RESET-SLE, RESET-MG to be presented in 1H26; design updates for SSc in 1H26 and MG mid-2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759138/000175913826000010/0001759138-26-000010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759138/000175913826000010/caba-20260323.htm
  HTML page:      https://secwatch.observer/filing/0001759138-26-000010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer